` SVRA (Savara Inc) vs S&P 500 Comparison - Alpha Spread

SVRA
vs
S&P 500

Over the past 12 months, SVRA has significantly outperformed S&P 500, delivering a return of +112% compared to the S&P 500's +12% growth.

Stocks Performance
SVRA vs S&P 500

Loading
SVRA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SVRA vs S&P 500

Loading
SVRA
S&P 500
Difference
www.alphaspread.com

Performance By Year
SVRA vs S&P 500

Loading
SVRA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Savara Inc vs Peers

S&P 500
SVRA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Savara Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

SVRA Intrinsic Value
2.38 USD
Overvaluation 66%
Intrinsic Value
Price
Back to Top